Whitehawk Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Whitehawk Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $13 per $100 of sales comes from others' credit, against $1 tied up three years earlier. Less money tied up than 95% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-35.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 67% of Healthcare companies in United States.
Cash Locked Ratio
−$13Money owed to suppliers is larger than money owed by customers plus stock: $13 per $100 of sales comes from others' credit, against $1 tied up three years earlier.
Less money tied up than 95% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 53%
Sales fell 53% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-53% / -18%In 3 years sales changed by -53% while total assets changed by -18%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+80%Cash, after subtracting all debt, equals 80% of its market value (net cash).
Higher than 84% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Whitehawk Therapeutics, Inc. made a loss over the last year. Whitehawk Therapeutics, Inc. owes $0.06 for every $1 it owns. Whitehawk Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossWhitehawk Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.00The share price is 1.00 times Whitehawk Therapeutics, Inc.'s book value per share, lower than 78% of Healthcare companies in United States.
Market cap
$183 MThe total market value of all of Whitehawk Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 59% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$183 MWhat Whitehawk Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.21Net worth divided by the number of shares. The share price of $3.21 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
-45.0%Whitehawk Therapeutics, Inc. lost 45.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
Owes vs Owns
0.06×Whitehawk Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneWhitehawk Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-73%Revenue fell 73% in the year to Dec 2025, and shrank 22% a year on average over 3 years.
Profit growth
LossWhitehawk Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-288.3%Whitehawk Therapeutics, Inc. lost $288 for every $100 of revenue.
Cash vs debt
Net cashWhitehawk Therapeutics, Inc. held $146 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Whitehawk Therapeutics, Inc.: $183 M ÷ $183 M (30 Jun 2026) = 1.0.
What is Whitehawk Therapeutics, Inc.'s return on equity?
Whitehawk Therapeutics, Inc. lost 45.0% of its shareholders' money over the last year, higher than 52% of Healthcare companies in United States.
How much does Whitehawk Therapeutics, Inc. owe compared with what it owns?
Whitehawk Therapeutics, Inc. owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Whitehawk Therapeutics, Inc. pay a dividend?
No. Whitehawk Therapeutics, Inc. does not currently pay a dividend.
Is Whitehawk Therapeutics, Inc.'s revenue growing?
Revenue fell 73% in the year to Dec 2025, and shrank 22% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.